Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024919314354 |
id |
doaj-2e2d670b48f24d0da27d45f04c41f401 |
---|---|
record_format |
Article |
spelling |
doaj-2e2d670b48f24d0da27d45f04c41f4012020-11-25T01:55:20ZengElsevierKidney International Reports2468-02492019-11-0141115461554Achievement of Low-Density Lipoprotein Cholesterol Targets in CKDZiad A. Massy0Jean Ferrières1Eric Bruckert2Céline Lange3Sophie Liabeuf4Maja Velkovski-Rouyer5Bénédicte Stengel6Carole AyavChristian CombeDenis FouqueLuc FrimatYves-Edouard HerpeMaurice LavilleZiad MassyBénédicte StengelCéline LangeKarine LegrandSophie LiabeufMarie MetzgerElodie SpeyerBruno MoulinGaétan LebrunÉric MagnantGabriel ChoukrounJean Philippe BourdenxMarie EssigRaymond AzarMustafa SmatiMohamed JamaliAlexandre KleinMichel DelahousseChristian CombeSéverine MartinEric ThervetZiad MassyXavier BelenfantPablo UrenaCarlos VelaLuc FrimatDominique ChauveauViktor PanescuFrançois GlowackiMaxime HoffmannMaryvonne HourmantDominique BesnierAngelo TestaPhilippe ZaouiCharles ChazotLaurent JuillardStéphane BurteyAdrien KellerNassim KamarDenis FouqueMaurice LavilleCentre for Research in Epidemiology and Population Health (CESP), Inserm UMRS 1018, Villejuif, France; University of Versailles-Saint Quentin, Univ Paris-Saclay, Villejuif, France; Department of Nephrology, CHU Ambroise Paré, APHP, Boulogne, FranceDepartment of Cardiology, Toulouse Rangueil University Hospital (CHU), Toulouse, France; Department of Epidemiology and Public Health, UMR INSERM 1027, INSERM – Université de Toulouse, Toulouse, FranceService d’Endocrinologie métabolisme et prévention cardiovasculaire, Unité fonctionnelle d’Aphérèse, Institut E3M et IHU cardiométabolique, Hôpital Pitié Salpêtrière, Paris, FranceAgence de Biomédecine, La Plaine-Saint Denis, FrancePharmacology Department, Amiens University Hospital, Amiens, FranceMedical department, MSD France, Courbevoie, FranceCentre for Research in Epidemiology and Population Health (CESP), Inserm UMRS 1018, Villejuif, France; Univ Paris-Sud, Univ Paris-Saclay, Villejuif, France; Correspondence: Bénédicte Stengel, CESP Equipe Rein-Coeur, 16 avenue P. Vaillant Couturier, 94807 Villejuif, France.Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterolhttp://www.sciencedirect.com/science/article/pii/S2468024919314354 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ziad A. Massy Jean Ferrières Eric Bruckert Céline Lange Sophie Liabeuf Maja Velkovski-Rouyer Bénédicte Stengel Carole Ayav Christian Combe Denis Fouque Luc Frimat Yves-Edouard Herpe Maurice Laville Ziad Massy Bénédicte Stengel Céline Lange Karine Legrand Sophie Liabeuf Marie Metzger Elodie Speyer Bruno Moulin Gaétan Lebrun Éric Magnant Gabriel Choukroun Jean Philippe Bourdenx Marie Essig Raymond Azar Mustafa Smati Mohamed Jamali Alexandre Klein Michel Delahousse Christian Combe Séverine Martin Eric Thervet Ziad Massy Xavier Belenfant Pablo Urena Carlos Vela Luc Frimat Dominique Chauveau Viktor Panescu François Glowacki Maxime Hoffmann Maryvonne Hourmant Dominique Besnier Angelo Testa Philippe Zaoui Charles Chazot Laurent Juillard Stéphane Burtey Adrien Keller Nassim Kamar Denis Fouque Maurice Laville |
spellingShingle |
Ziad A. Massy Jean Ferrières Eric Bruckert Céline Lange Sophie Liabeuf Maja Velkovski-Rouyer Bénédicte Stengel Carole Ayav Christian Combe Denis Fouque Luc Frimat Yves-Edouard Herpe Maurice Laville Ziad Massy Bénédicte Stengel Céline Lange Karine Legrand Sophie Liabeuf Marie Metzger Elodie Speyer Bruno Moulin Gaétan Lebrun Éric Magnant Gabriel Choukroun Jean Philippe Bourdenx Marie Essig Raymond Azar Mustafa Smati Mohamed Jamali Alexandre Klein Michel Delahousse Christian Combe Séverine Martin Eric Thervet Ziad Massy Xavier Belenfant Pablo Urena Carlos Vela Luc Frimat Dominique Chauveau Viktor Panescu François Glowacki Maxime Hoffmann Maryvonne Hourmant Dominique Besnier Angelo Testa Philippe Zaoui Charles Chazot Laurent Juillard Stéphane Burtey Adrien Keller Nassim Kamar Denis Fouque Maurice Laville Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD Kidney International Reports |
author_facet |
Ziad A. Massy Jean Ferrières Eric Bruckert Céline Lange Sophie Liabeuf Maja Velkovski-Rouyer Bénédicte Stengel Carole Ayav Christian Combe Denis Fouque Luc Frimat Yves-Edouard Herpe Maurice Laville Ziad Massy Bénédicte Stengel Céline Lange Karine Legrand Sophie Liabeuf Marie Metzger Elodie Speyer Bruno Moulin Gaétan Lebrun Éric Magnant Gabriel Choukroun Jean Philippe Bourdenx Marie Essig Raymond Azar Mustafa Smati Mohamed Jamali Alexandre Klein Michel Delahousse Christian Combe Séverine Martin Eric Thervet Ziad Massy Xavier Belenfant Pablo Urena Carlos Vela Luc Frimat Dominique Chauveau Viktor Panescu François Glowacki Maxime Hoffmann Maryvonne Hourmant Dominique Besnier Angelo Testa Philippe Zaoui Charles Chazot Laurent Juillard Stéphane Burtey Adrien Keller Nassim Kamar Denis Fouque Maurice Laville |
author_sort |
Ziad A. Massy |
title |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
title_short |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
title_full |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
title_fullStr |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
title_full_unstemmed |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
title_sort |
achievement of low-density lipoprotein cholesterol targets in ckd |
publisher |
Elsevier |
series |
Kidney International Reports |
issn |
2468-0249 |
publishDate |
2019-11-01 |
description |
Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol |
url |
http://www.sciencedirect.com/science/article/pii/S2468024919314354 |
work_keys_str_mv |
AT ziadamassy achievementoflowdensitylipoproteincholesteroltargetsinckd AT jeanferrieres achievementoflowdensitylipoproteincholesteroltargetsinckd AT ericbruckert achievementoflowdensitylipoproteincholesteroltargetsinckd AT celinelange achievementoflowdensitylipoproteincholesteroltargetsinckd AT sophieliabeuf achievementoflowdensitylipoproteincholesteroltargetsinckd AT majavelkovskirouyer achievementoflowdensitylipoproteincholesteroltargetsinckd AT benedictestengel achievementoflowdensitylipoproteincholesteroltargetsinckd AT caroleayav achievementoflowdensitylipoproteincholesteroltargetsinckd AT christiancombe achievementoflowdensitylipoproteincholesteroltargetsinckd AT denisfouque achievementoflowdensitylipoproteincholesteroltargetsinckd AT lucfrimat achievementoflowdensitylipoproteincholesteroltargetsinckd AT yvesedouardherpe achievementoflowdensitylipoproteincholesteroltargetsinckd AT mauricelaville achievementoflowdensitylipoproteincholesteroltargetsinckd AT ziadmassy achievementoflowdensitylipoproteincholesteroltargetsinckd AT benedictestengel achievementoflowdensitylipoproteincholesteroltargetsinckd AT celinelange achievementoflowdensitylipoproteincholesteroltargetsinckd AT karinelegrand achievementoflowdensitylipoproteincholesteroltargetsinckd AT sophieliabeuf achievementoflowdensitylipoproteincholesteroltargetsinckd AT mariemetzger achievementoflowdensitylipoproteincholesteroltargetsinckd AT elodiespeyer achievementoflowdensitylipoproteincholesteroltargetsinckd AT brunomoulin achievementoflowdensitylipoproteincholesteroltargetsinckd AT gaetanlebrun achievementoflowdensitylipoproteincholesteroltargetsinckd AT ericmagnant achievementoflowdensitylipoproteincholesteroltargetsinckd AT gabrielchoukroun achievementoflowdensitylipoproteincholesteroltargetsinckd AT jeanphilippebourdenx achievementoflowdensitylipoproteincholesteroltargetsinckd AT marieessig achievementoflowdensitylipoproteincholesteroltargetsinckd AT raymondazar achievementoflowdensitylipoproteincholesteroltargetsinckd AT mustafasmati achievementoflowdensitylipoproteincholesteroltargetsinckd AT mohamedjamali achievementoflowdensitylipoproteincholesteroltargetsinckd AT alexandreklein achievementoflowdensitylipoproteincholesteroltargetsinckd AT micheldelahousse achievementoflowdensitylipoproteincholesteroltargetsinckd AT christiancombe achievementoflowdensitylipoproteincholesteroltargetsinckd AT severinemartin achievementoflowdensitylipoproteincholesteroltargetsinckd AT ericthervet achievementoflowdensitylipoproteincholesteroltargetsinckd AT ziadmassy achievementoflowdensitylipoproteincholesteroltargetsinckd AT xavierbelenfant achievementoflowdensitylipoproteincholesteroltargetsinckd AT pablourena achievementoflowdensitylipoproteincholesteroltargetsinckd AT carlosvela achievementoflowdensitylipoproteincholesteroltargetsinckd AT lucfrimat achievementoflowdensitylipoproteincholesteroltargetsinckd AT dominiquechauveau achievementoflowdensitylipoproteincholesteroltargetsinckd AT viktorpanescu achievementoflowdensitylipoproteincholesteroltargetsinckd AT francoisglowacki achievementoflowdensitylipoproteincholesteroltargetsinckd AT maximehoffmann achievementoflowdensitylipoproteincholesteroltargetsinckd AT maryvonnehourmant achievementoflowdensitylipoproteincholesteroltargetsinckd AT dominiquebesnier achievementoflowdensitylipoproteincholesteroltargetsinckd AT angelotesta achievementoflowdensitylipoproteincholesteroltargetsinckd AT philippezaoui achievementoflowdensitylipoproteincholesteroltargetsinckd AT charleschazot achievementoflowdensitylipoproteincholesteroltargetsinckd AT laurentjuillard achievementoflowdensitylipoproteincholesteroltargetsinckd AT stephaneburtey achievementoflowdensitylipoproteincholesteroltargetsinckd AT adrienkeller achievementoflowdensitylipoproteincholesteroltargetsinckd AT nassimkamar achievementoflowdensitylipoproteincholesteroltargetsinckd AT denisfouque achievementoflowdensitylipoproteincholesteroltargetsinckd AT mauricelaville achievementoflowdensitylipoproteincholesteroltargetsinckd |
_version_ |
1724983899925250048 |